Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Usefulness of nutraceuticals in migraine prophylaxis.
D'Onofrio F, Raimo S, Spitaleri D, Casucci G, Bussone G. D'Onofrio F, et al. Neurol Sci. 2017 May;38(Suppl 1):117-120. doi: 10.1007/s10072-017-2901-1. Neurol Sci. 2017. PMID: 28527067 Review.
Trends of recanalization therapies and state of art for ischemic stroke treatment in Campania region, Italy.
Spina E, Candelaresi P, Volpe G, D'Onofrio F, Spitaleri D, Martusciello G, Piccirillo G, Briganti F, Muto M, Feleppa M, Sparaco M, Manto A, Cuomo T, Ascione S, Ripa P, Romano DG, Andreone V, Manganelli F, Napoletano R. Spina E, et al. Neurol Sci. 2022 Dec;43(12):6865-6870. doi: 10.1007/s10072-022-06321-3. Epub 2022 Sep 8. Neurol Sci. 2022. PMID: 36074192 Free PMC article.
The Impact of Covid-19 Lockdown on Stroke Admissions and Treatments in Campania.
Candelaresi P, Manzo V, Servillo G, Muto M, Barone P, Napoletano R, Saponiero R, Andreone V, Palma V, Spitaleri D, D'Onofrio F, Maniscalco G, Salvatore S, Leone G, Capone E, Schettino C, Romano D, Martusciello G, Miniello S, Mazzaferro MP, Ascione S. Candelaresi P, et al. J Stroke Cerebrovasc Dis. 2021 Jan;30(1):105448. doi: 10.1016/j.jstrokecerebrovasdis.2020.105448. Epub 2020 Nov 4. J Stroke Cerebrovasc Dis. 2021. PMID: 33166767 Free PMC article.
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study.
Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Lovati C, Bertuzzo D, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Schiano Di Cola F, Ranieri A, Colombo B, Bono F, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group. Vernieri F, et al. Eur J Neurol. 2022 Apr;29(4):1198-1208. doi: 10.1111/ene.15197. Epub 2021 Dec 6. Eur J Neurol. 2022. PMID: 34826192
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group. Vernieri F, et al. J Headache Pain. 2021 May 3;22(1):35. doi: 10.1186/s10194-021-01247-1. J Headache Pain. 2021. PMID: 33941080 Free PMC article.
342 results